High Performance Antigen Diagnostics

Agency:
State: District of Columbia
Type of Government: Federal
FSC Category:
  • A - Research and development
NAICS Category:
  • 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Set Aside: No Set aside used
Posted Date: Jun 17, 2026
Due Date: Jul 17, 2026
Solicitation No: RRPV-HPAD
Original Source: Please Login to View Page
Contact information: Please Login to View Page
Bid Documents: Please Login to View Page

Description

Follow
High Performance Antigen Diagnostics
Active
Contract Opportunity
Notice ID
RRPV-HPAD
Related Notice
Department/Ind. Agency
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Office
ASPR BARDA DIV CONTRACTS MGMT & ACQ
Looking for contract opportunity help?

APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.

APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.

The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).

General Information
  • Contract Opportunity Type: Sources Sought (Original)
  • Original Published Date: Jun 17, 2026 01:24 pm EDT
  • Original Response Date: Jul 17, 2026 01:00 pm EDT
  • Inactive Policy: 15 days after response date
  • Original Inactive Date: Aug 01, 2026
  • Initiative:
    • None
Classification
  • Original Set Aside: No Set aside used
  • Product Service Code: AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
  • NAICS Code:
    • 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
  • Place of Performance:
    Washington , DC
    USA
Description

“High Performance Antigen Diagnostics” Request for Information (RFI) Purpose The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.




Attachments/Links
Contact Information
Contracting Office Address
  • 200 C Street, SW
  • Washington , DC 20515
  • USA
Primary Point of Contact
Secondary Point of Contact


History
  • Jun 17, 2026 01:24 pm EDTSources Sought (Original)
Get Government Bids Like This by Email Receive daily bid alerts that match your keywords, business categories, and target regions.
View Sample Report Start Free Trial

See Also

Office of Hazardous Materials...

Follow Office of Hazardous Materials Safety Research Initiative - FY2026 BROAD AGENCY ANNOUNCEMENT

TRANSPORTATION, DEPARTMENT OF

Due by 11/18/2026

K-12 Schools Behavioral Threa...

Follow K-12 Schools Behavioral Threat Assessment and Management (BTAM) Implementation and State Policy

HOMELAND SECURITY, DEPARTMENT OF

Due by 9/17/2026

Strategic Capabilities Office...

Follow Strategic Capabilities Office Broad Agency Announcement Active Contract Opportunity Notice ID HQ0034-SCO-24-BAA-0001

Federal Agency

Due by 1/16/2029

NEEDIPEDIA - COMMERCIAL SOLUT...

Follow NEEDIPEDIA - COMMERCIAL SOLUTIONS OPENING - CSO Active Contract Opportunity Notice ID

DEPT OF DEFENSE

Due by 12/26/2028

* Disclaimer: This website provides information about bids, requests for proposals (RFPs), or requests for qualifications (RFQs) for convenience only and does not serve as an official public notice. Individuals who wish to respond to or inquire about bids, RFPs, or RFQs should contact the relevant government department directly.